Nowadays, medical technology is steadily growing, but the mortality rate for cancer is still high. According to the National Cancer Institute in 2016, an estimated 1,685,210 new cases of cancer will be diagnosed in the United States and 595,690 people will die from the disease. Most cancer patients die because they do not get an early diagnosis. The majority of malignant tumors can be treated successfully if detected early. Cancer that’s diagnosed at an early stage, before it’s had the chance to get too big or spread is more likely to be treated successfully. If the cancer has spread, treatment becomes more difficult, and generally a person’s chances of surviving are much lower. Therefore, prevention diagnose is important than any others. Millions of people die preventable deaths every year and this can be due to environmental factors, lifestyle choices, and genetic susceptibility. Leading causes for the majority of preventable deaths include pancreatic cancer, cardiovascular disease, diabetes, obesity, chronic respiratory disease, and a number of infectious diseases. With a constant rise in the number of people getting affected by these chronic diseases, the preventive healthcare industry has gained a lot of momentum across the globe.
PHARMSWELL-BIO owns a subsidiary called CUBEBIO, and is responsible for sales and distribution inside and outside of the country. They have developed a diagnostic tool called a ‘T-marker’ for cancer detection based on the trend of preventive medicine. Nowadays, although 25 cancer markers have been commercialized for the 17 types of cancer, all of them are serum bio-markers which are able to diagnose with blood, but cancer marker using urine was not commercialized yet. The product for cancer diagnosis by using ‘T-marker’ has been already released before in the US, Europe and Asian countries. Since the existing product used Millon-method in order to diagnose cancer by using mercury, other countries except China prohibited product sale. CUBEBIO is the world’s first product that can distinguish cancer patients by using colorimetric determination method through enzyme reaction rather than mercury for ‘T-marker’, which can be found in urine of cancer patients.
The ‘T-marker’, developed by CUBEBIO, is a diagnostic kit that compares the urine components of cancer patients with the T-marker enzymes. Users can diagnose 14 types of cancers at the same time. It is very simple, quick and stable in vitro diagnostic by using enzyme method. There is no side effect such as radiation exposure and users can detect early stages of cancer. Existing methods such as the PET and MRI can only detect more than 5 mm size of cancer and builds low accuracy as it depends on the reading ability of observer. Since ‘T-Marker’ is easily found more than 50 to 150% in normal people than cancer patients, it has high sensitivity and specificity in 14 types of cancer. According to the result of the element analysis conducted by the Korea Basic Science Institute, the T-markers show the data of over expression/hypo-expression in the urine sample of the cancer patient than the ordinary sample.
CUBEBIO received clinical approval from the Ministry of Food and Drug Administration and conducted clinical test on T-markers at Asan Hospital in South Korea. In addition, 23 patents were registered among a total of 30 patents, including the core patent for enzyme substance. In the future, this cancer diagnosis kit will be a signal for early detection and survival rate of cancer. PHARMSWELL-BIO has been checking the possibility of global pharmaceutical companies and global market penetration and will try to enter the US and European markets that have high rates of cancer.
PHARMSWELL-BIO
▲ PHARMSWELL-BIO Co., Ltd
▲ CEO: Young-Jin Jang
▲ T: +822 569-7610
Irene Kim
K-Herald Korea
(Los Angeles Times Advertising Supplement)
